Intraovarian platelet-rich plasma (PRP) infusion appeared to benefit low prognosis IVF patients; however, when...

To assess whether in-office intraovarian PRP injections among patients with a history of a low euploid embryo yield following freeze-all PGT-A IVF cycle improves transferable embryo yield when compared to controls.

A retrospective case-control study, between March 2022 and December 2024 where all poor outcome patients who underwent in-office intraovarian PRP injection prior to a repeat freeze-all PGT-A IVF cycle were compared to controls with no intervention between cycles. The primary outcome was transferable embryo yield. Secondary outcomes included: blastocyst yield, aneuploidy rate, and euploid yield.

Thirty-two patients met the inclusion criteria and were compared to 309 controls. Mean age for the PRP and control group were 38.3 ± 3.1 and 38.4 ± 3.7 (p = 0.91) respectively. Mean AMH for the PRP group was 1.6 ± 1.1 ng/mL as compared to 1.5 ± 1.0 ng/mL (p = 0.34). Following PRP the blastocyst, euploid and transferable embryo yield increased; however, when compared to controls, there were no differences in IVF outcomes. For patients with an AMH ≥ 1, the euploid yield and transferable embryo yield increased by fivefold; however, there was no difference when compared to the control. For patients with an AMH < 1, there were no differences in euploid or transferable embryo yield following PRP.

Although there was an improvement in transferable embryos yielded following PRP, no difference was observed compared to the control group, as the control with a poor initial cycle experienced regression to the mean which may also be a source of bias in the PRP group.